Health Highlight Wed. 1, Mar.
Today's highlights: New research on the effects of sibling aggression; discussion around the use of psychedelics as a potential treatment modality; and the FDA's 2/28 Roundup.
The Health Highlights workflow is powered by Glasp.co To learn more, visit:
or begin curating by clicking the invite button.🔺 “Sibling aggression and abuse go beyond rivalry – bullying within a family can have lifelong repercussions”
✍️ By: Corinna J. Tucker, Tanya R. Whitworth • @tanyawhitworth @ConversationUS
🏷️ Tags: #siblings #aggressivebehavior #mentalhealth #childrenshealth #abuse
👉 More: https://glasp.co/#/ItsTechnical
Conflict among siblings is widely viewed as normal but, in the past decade, a new body of research consistently shows that sibling aggression and abuse are far from harmless – and can have lifelong repercussions.
Confusion about the difference between rivalry and sibling aggression prevents people from recognizing it.
Aggressive behavior is characterized by an intent to cause harm, including physical pain and humiliation. Many behaviors between siblings fit this definition.
Sibling aggression is linked with poor mental health.
Origins of sibling aggression and abuse The cause of sibling aggression can be rooted in family dynamics.
In cases of sibling abuse, teaching siblings conflict resolution skills is not appropriate. Professional help is recommended.
🔺 “The Promise and Perils of Psychedelics”
✍️ By: Rachel Gotbaum, Intention to Treat (podcast) • @NEJM
🌐 URL: https://www.nejm.org/doi/full/10.1056/NEJMp2300936
🏷️ Tags: #psychedelics #mushrooms #LSD #PTSD #depression #research
👉 More: https://glasp.co/#/ItsTechnical
Psychedelics have been used to treat mental health issues for a long time, but research was shut down in the late 1960s.
Recently, studies have been conducted to see if psychedelics can help with depression, PTSD, alcoholism, and eating disorders.
Results have been promising, showing that a synthetic psilocybin compound can help with depression.
However, there are risks associated with psychedelics, such as dangerous behavior and the onset of new psychiatric conditions.
Therefore, researchers are careful to monitor participants and screen for vulnerabilities.
🔺 “FDA Roundup: February 28, 2023”
✍️ By: FDA Office of Media Affairs • @US_FDA
🌐 URL: https://www.fda.gov/news-events/press-announcements/fda-roundup-february-28-2023
🏷️ Tags: #FDA #coronavirus #covid19 #longcovid #research #infectiousdisease
👉 More: https://glasp.co/#/ItsTechnical
Today, the FDA is withdrawing a 2005 proposed rule and issued a Letter to Health Care Providers about the potential risk of early structural valve deterioration with Abbott Trifecta valves.
The FDA also issued an emergency use authorization for the first over-the-counter at-home diagnostic test that can identify and tell the difference between influenza A and B and SARS-CoV-2.
The FDA also updated the Breakthrough Devices Program online metrics and authorized the EnteraSense Ltd. PillSense System for marketing.
Additionally, the FDA will host a virtual public meeting on Patient-Focused Drug Development for Long COVID.
As of today, 444 tests and sample collection devices are authorized by the FDA under emergency use authorizations, including 45 antigen tests and eight molecular tests for serial screening programs.